Aspire Biopharma Holdings, Inc. (ASBP)
NASDAQ: ASBP · Real-Time Price · USD
5.41
-0.18 (-3.22%)
At close: May 22, 2026, 4:00 PM EDT
5.45
+0.04 (0.74%)
After-hours: May 22, 2026, 7:59 PM EDT

Aspire Biopharma Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
0.030.01---
Cost of Revenue
0.030.01---
Gross Profit
0.01-0---
Selling, General & Admin
2.8318.431.071.340.98
Research & Development
0.960.920.14--
Total Operating Expenses
3.7919.351.211.340.98
Operating Income
-3.79-19.35-1.21-1.34-0.98
Interest Income
0.01----
Interest Expense
1.68.530.1--
Other Non-Operating Income (Expense)
0.494.32---
Total Non-Operating Income (Expense)
-1.58-5.13-0.1--
Pretax Income
-5.36-24.48-1.31-1.34-0.98
Net Income
-5.36-24.48-1.31-1.34-0.98
Net Income to Common
-5.36-24.48-1.31-1.34-0.98
Shares Outstanding (Basic)
00000
Shares Outstanding (Diluted)
00000
Shares Change (YoY)
89.24%116.69%1697.29%--
EPS (Basic)
-548.27-491.40-57.00-0.032105.93
EPS (Diluted)
-548.27-491.40-57.00-0.032105.93
Shares Outstanding
0.170.120.0200
Free Cash Flow
-6.21-4.92-0.27-0.65-1.41
Free Cash Flow Per Share
-10.08-98.80-11.53-510.42-1101.01
Gross Margin
16.30%-1.87%---
Operating Margin
-4763.91%-312017.00%---
Profit Margin
-9326.85%-394725.00%---
FCF Margin
-17972.70%-79385.50%---
EBITDA
5.94-11.33-1.21-1.33-0.98
EBITDA Margin
17178.30%-182713.00%---
EBIT
-3.79-19.35-1.21-1.34-0.98
EBIT Margin
-4763.91%-312017.00%---
Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q